Evidence map›Paper›PMID 29463472›Full record

ArticleEBioMedicine2018

Interferon Gamma Induces Reversible Metabolic Reprogramming of M1 Macrophages to Sustain Cell Viability and Pro-Inflammatory Activity.

Feilong Wang, Song Zhang, Ryounghoon Jeon, Ivan Vuckovic, Xintong Jiang, Amir Lerman, Clifford D Folmes, Petras D Dzeja, Joerg Herrmann

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 213 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
213citing papers in PubMed, 1 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

213 citing papers in PubMed, 1 synthesis or guideline pooled it, 316 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Restricted MHC-II trafficking inbioRxiv : the preprint server for biology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

153 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Feilong WangDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States.
Song ZhangDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States.
Ryounghoon JeonDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States.
Ivan VuckovicDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States.
Xintong JiangKarolinska Institutet, Stockholm, Sweden.
Amir LermanDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States.
Clifford D FolmesMayo Clinic, Scottsdale, AZ, United States.
Petras D DzejaDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States.
Joerg HerrmannDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States. Electronic address: herrmann.joerg@mayo.edu.
Mayo Clinic in Arizona · USKarolinska Institutet · SE

Funding

TECHNOLOGY NMR SPECTROSCOPYU24DK100469 · NIDDK · MAYO CLINIC ROCHESTER · PI NAIR, K SREEKUMARAN · 2013 to 2017
$9.0M
Adenylate Kinase in Heart Energetics and Metabolic SignalingR01HL085744 · NHLBI · MAYO CLINIC ROCHESTER · PI DZEJA, PETRAS P · 2007 to 2016
$3.4M
The pathophysiological role of the immunoproteasome in atherosclerosisK08HL116952 · NHLBI · MAYO CLINIC ROCHESTER · PI HERRMANN, JOERG · 2014 to 2018
$750k
Metabolic reprogramming in pluripotent induction and cardiac lineage specificatioR00HL121079 · NHLBI · MAYO CLINIC ARIZONA · PI FOLMES, CLIFFORD D · 2017 to 2019
$747k
Metabolic reprogramming in pluripotent induction and cardiac lineage specificatioK99HL121079 · NHLBI · MAYO CLINIC ROCHESTER · PI FOLMES, CLIFFORD D · 2014 to 2015
$279k
NHLBI NIH HHS K08 HL116952NHLBI NIH HHS K99 HL121079NHLBI NIH HHS R00 HL121079NHLBI NIH HHS R01 HL085744NIDDK NIH HHS U24 DK100469
6 · The paper itself

Abstract

Classical activation of M1 macrophages with lipopolysaccharide (LPS) is associated with a metabolic switch from oxidative phosphorylation to glycolysis. However, the generalizability of such metabolic remodeling to other modes of M1 macrophage stimulation, e.g. type II interferons (IFNs) such as IFNγ, has remained unknown as has the functional significance of aerobic glycolysis during macrophage activation. Here we demonstrate that IFNγ induces a rapid activation of aerobic glycolysis followed by a reduction in oxidative phosphorylation in M1 macrophages. Elevated glycolytic flux sustains cell viability and inflammatory activity, while limiting reliance on mitochondrial oxidative metabolism. Adenosine triphosphate (ATP) distributed by aerobic glycolysis is critical for sustaining IFN-γ triggered JAK (Janus tyrosine kinase)-STAT-1 (Signal Transducer and Activator of Transcription 1) signaling with phosphorylation of the transcription factor STAT-1 as its signature trait. Inhibition of aerobic glycolysis not only blocks the M1 phenotype and pro-inflammatory cytokine/chemokine production in murine macrophages and also human monocytes/macrophages. These findings extend on the potential functional role of immuno-metabolism from LPS- to IFNγ-linked diseases such as atherosclerosis and autoimmune disease.

Indexed as

Adenosine TriphosphateAnimalsCell DifferentiationCell SurvivalChemokinesCitric Acid CycleDeoxyglucoseFemaleGalactoseGlycolysisHumansHypoxia-Inducible Factor 1, alpha SubunitInflammationInterferon-gammaJanus KinasesLactic AcidAdenosine TriphosphateChemokinesDeoxyglucoseGalactoseHif1a protein, mouseHypoxia-Inducible Factor 1, alpha SubunitInterferon-gammaJanus KinasesLactic AcidNitric OxideProto-Oncogene Proteins c-aktPyruvic AcidReactive Oxygen SpeciesSTAT1 Transcription FactorImmunometabolismInflammationInterferon gammaInterleukin-1 betaMacrophage

Identifiers

PMID29463472
PMCPMC5953001
OpenAlexW2792935190

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.